Boston Scientific Corporation · NYSE:BSX
Boston Scientific — Guidant — SPAC Merger (March 2006)
70 slides from Boston Scientific's SPAC merger presentation, Mar 15, 2006
Slide 1: Boston Scientific: Delivering what's next
Boston Scientific Detivering what's next.”
Slide 2: Safe Harbor: Forward-Looking Statements
Safe Harbor: Senne Forward-Looki fatements This presentation contains “forward-looking statements,” including, among other statements, statements regarding the proposed business combination between Boston Scientific Corporation and Guidant Corporation, and the anticipated consequences and benefits o
Slide 3: Safe Harbor: Additional Information
Safe Harbor: Additional Information gBostone Boston Scientific and Guidant have filed a definitive prospectus/joint proxy statement with the SEC in connection with the proposed transaction. The material contained herein is not @ substitute forthe definitive prospectus/joint proxy statement or any ot
Slide 4: Agenda
Agenda Bostony. Scientific PF Introduction Larry Best, Executive Vice President and Business Update TAXUS Clinical Program Update Cardiovascular Business Update Q&A Chief Financial Officer Paul LaViolette, Chief Operating Officer Joerg Koglin, M.D., Senior Medical Director, Vice President, Cardiovas
Slide 5: Scientific
Be Scientific Detivering what's next.”
Slide 6: Key Take-Aways
Key Take-Aways Senne ‘S Global Leadership (x-Japan) strengthening — U.S. TAXUS® share stable at 54% * Q4 TAXUS® Liberté™ Launch — Int'l TAXUS share stable 2 50% * TAXUS® Liberté™ Launch Expansion + Endeavor™ / Cypher® share exchange + Compelling pipeline, progressing steadily — Apex, Barracuda, Peta
Slide 7: Key Take-Aways
Key Take-Aways Bostone, _ Scientific + Warning Letter remediation making measured progress with new systems ¢ Guidant on track — VI Divestiture and close — Week of April 3% — Diversification and Growth * Cardiovascular / Full BSC continues strong performance
Slide 8: Corporate Warning Letter
Corporate Warning Letter Bostone. Internal P Underway Quality System Components ¢« Management Responsibility Product Surveillance/MDR Reporting + Field Action Decision Making CAPA + Leading BSC change that will be —Company- wide —Cross-functional — Rapid —Comprehensive
Slide 9: Warning Letter Response Status
Warning Letter Response Status gBostone ¢ Filed response with FDA 3/3 + Currently under review ° Face to Face meetings being scheduled * Monthly updates to be provided to FDA * On-going execution of remediation + Measured progress + Expansion of new systems * Global Complaint System + Global CAPA Sy
Slide 10: Scientific
Be Scientific Detivering what's next.”
Slide 11: Clinical Research Update
Boston Scientific Analyst Meeting Clinical Research Update @ L- Joerg Koglin, MD Senior Medical Director, Vice President Medical Sciences
Slide 12: The DES Clinical Trial Landscape in Perspective
The DES Clinical Trial Landscape in Perspective 1 Year thtetenenentntetiten teeetterte tenet i aaeT tt HH 94487 Hy toetteneeteneenentt eaeenee tent tt tite tit ttt ttt ttt ttt t laeeppeRee LLL TT netoor nent etttitttt Mots Mach TO 2 Years ttteteeeeetententie ttt PHL 3 Years eitteeneeeeettetiet be n=
Slide 13: Stairway to Evidence-Based Medicine
Stairway to Evidence-Based Medicine multi-vessel bifurcate CT left main disease FW smrax @snmax @ FReEvom f Dennax CORPAL SIF blinded, acively controlled tral involving an independent core involving only [Won @ prison @rwusvisr Jon @ sien ee Green @xesr @ TRIAL: randomized, muicenter, Taxus vessels
Slide 14: SYNTAX: Expanding into 3-Vessel and Left Main
@L- SYNTAX: Expanding into 3-Vessel and Left Main All patients with Left main and/or 3-Vessel Disease Minimal In- or Exclusion Criteria Local Heartteam (Interventional Cardiologist & Cardiothoracic Surgeon) eligible for both treatment options Randomized Trial Nested Registries rr | Mots, Mach 13,208
Slide 15: SYNTAX on Track to Address Remaining Needs
SYNTAX on Track to Address Remaining Needs Indication Expansion to 3-Vessel Disease & LM Enrollment status Cn) Randomized 4101 patients 5 é as of March 10, 2006 Jul Aug Sep Qst Nov Dec Jan Feb Mar 6 @ 6 6 6 6 6 6 6 ‘ACC Gis Reseach Update 6
Slide 16: SYNTAX — Expanding Procedural Complexity
SYNTAX — Expanding Procedural Complexity # Lesions per patient # of stents per patients Patients with total stent length 2100 mm Site reported as of March 10, 2006
Slide 17: SYNTAX - Addressing the Remaining Needs
ee SYNTAX - Addressing the Remaining Needs Site reported as of March 10, 2006 Aeot, Mach 13,2005 ‘ACC Cowal Reseach Update oT
Slide 18: SYNTAX — in perspective
SYNTAX — in perspective 2- and 3-vessel disease in diabetics Superiority trial 2300 patients planned 5 year MACCE Study start April 20 | vw 100 patients 1101 patients (4%) enrolled at 50 sites (62%) enrolled at 71 sites
Slide 19: TAXUS V ISR - Mastering Another Step
@L- TAXUS V ISR - Mastering Another Step left main disease multi-vessel disease | @swrax bifurcated lesions | @sywtax CTO} @smrax jong A2betes)) [(@}BORUS V ISR lesions | @rwwuswi small @twusv vessels | @twusvi @raxusiv @ wus v @rwusv REALTY enn J Increasing complexity a i] Mots, Mach 13,208 ‘ACC Gi
Slide 20: TAXUS Changing the Way Patients Are Treated
TAXUS Changing the Way Patients Are Treated Paclitaxel-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents The TAXUS V ISR Randomized Tal simultaneous publication in JAMA available online since Mar 12, 2006 available in print on Mar 15 2006 @L-
Slide 21: Why In-Stent Restenosis?
Why In-Stent Restenosis ? > an unsolved clinical problem - 12% of the US market is still BMS (150,000 stents in 2005) ~ 50% of the OUS market is still BMS (1,000,000 stents in 2005) ~ an excellent surrogate for lesion complexity “if it works well in ISR, it will work well in all lesions” - awell def
Slide 22: In-stent Restenosis - an Unsolved Clinical Problem
@L- In-stent Restenosis - an Unsolved Clinical Problem Focal Diffuse Proliferative Total Occlusion Mehran et al; Circulation 1999; 100: 1872-1878 Costantino et al.; Am J Cardiol 2001; 92: 1214-1217 06 2
Slide 23: In-Stent Restenosis in TAXUS V ISR
In-Stent Restenosis in TAXUS V ISR before procedure after procedure 9 months after lesion length 39 mm vessel diameter 2.5 mm diameter stenosis 77% 2 TAXUS Express stents 3.0x24mm and 3.0x32 mm | Aeot, Mach 13,2006 ‘ACC Gis Reseach Update B
Slide 24: Study Design
@u- Study Design Patients with in-stent restenosis of a previously implanted bare metal stents in a native coronary artery lesions < 46mm in length and > 2.5mm to < 3.75mm in diameter (n=396) rachytherapy (n=201) Primary endpoint — 9-month Target Vessel Revascularization (TVR) powered for sequential
Slide 25: TAXUS Approach
TAXUS Approach PTCA catheter Old stent New stent SS 5mm. In-Stent 5mm. —— -— Proximal Distal edge edge Injury Segment Area in which balloon was inflated against the wall Analysis Segment Stented segment plus 5 mm on each edge Mots, Mach 13,208 ‘ACC Gis Reseach Update %
Slide 26: Vascular Brachytherapy Approach
@L- Vascular Brachytherapy Approach PTCA catheter Olden B radiation source Injury Segment Area in which balloon was inflated against the wall 5mm Radiation Segment 5mm - + ++ ropa ‘Area exposed to brachytherapy ue Analysis Segment Raziation segment plus 5 mm on each edge ‘Ato, Mach 13,206 ‘ACC Gis R
Slide 27: Patient Enrollment and Follow-up
@u- Patient Enrollment and Follow-up TAX Randomized rachytherapy TAXUS (n= (n=195) 9m Follow-Up (n=3865; 97.2%) rachytherapy (n=194) ‘Ato, Mach 13,206 ‘ACC Gis Reseach Update Fy
Slide 28: Primary Superiority Endpoint Met
Primary Superiority Endpoint Met - Reduced 9-Month TLR and TVR with TAXUS [Brachytherapy (n=194) (MB STAXUS (n=191) Events (%) @L-
Slide 29: Cumulative TVR out to 9-Month
@u- Cumulative TVR out to 9-Month - Superior Outcomes for TAXUS with Early Separation — Brachytherapy (n=201) — TAXUS (n=195) g g Log-Rank P=0.04 g Cumulative Event Rate z 120 150 180 210 240 Days Since Index Procedure
Slide 30: 9-Month MACE Advantage Driven by Reduced TVR
@L- 9-Month MACE Advantage Driven by Reduced TVR [J Brachytherapy (n=194) (MB STAXUS (n=191) p>0.99 p=0.50 p=0.45 p=0.046 p=0.03 p=0.02 19.6 S ; Q = oO 2 Lu NE 1 0 0 1 9 6 34-20 3822 39 . 22 Cardiac QWave NonQ TVR TVF MACE Death Ml Wave MI
Slide 31: 9-Month Target Vessel Thrombosis Comparable
@4- 9-Month Target Vessel Thrombosis Comparable In-Hospital MM D/C - 30 days fMM}31 days-6mo | |6mo-9mo Brachy- therapy 1.6% TAXUS (i191) Target Vessel Thrombosis (%)
Slide 32: Evolving Statistical Standards
Evolving Statistical Standards Normal distribution (bell-shaped, symmetric) Non-Normal distribution (skewed, asymmetric) Reported as statistical Reported as ‘mean + standard deviation’ (GIRCIES Tak} part ‘median (interquartile range)’ Parametric comparison taking ch “ a BMA Non-parametric comparison
Slide 33: MLD - Analysis Segment
MLD - Analysis Segment 100% 9-Month Median (QR) j = VBT: 1.55 (1.05, 1.91) 10% L — TAXUS: 1.99 (1.03, 2.25) Percentile Pgeeees Minimum Lumen Diameter (mm) Brachy Pre-proc Brachy Postproc Brachy 9m follow-up + TAXUS Pre-proc TAXUS Post-proc —_TAXUS 9m follow-up
Slide 34: Late Loss - Paired Angiographic Analysis
Late Loss - Paired Angiographic Analysis [J Brachytherapy {MB Taxus il & In-Stent Analysis Segment @L-
Slide 35: 9-Month Restenosis Superior in TAXUS
9-Month Restenosis Superior in TAXUS (10 Brachytherapy (i Taxus % Patients N= 8124 11453 4272 © S4N69 1271 «GSI anes Proximal In-Stent Injury Distal Edge Segment Edge @L- §3470 = 2572 Analysis Segment
Slide 36: No Differences in Aneurysms
@4- No Differences in Aneurysms Post-Procedure 9-Month Follow-up Paired Analysis Resolved 1 (0.6%) Persistent 5 (2.9%) 1 (0.6%) Late Acquired 3 (1.8%) 1 (0.6%)
Slide 37: Conclusions — Superiority in a Non-Inferiority Trial
@L- Conclusions — Superiority in a Non-Inferiority Trial The use of TAXUS Express for treatment of in-stent restenosis has been shown to be - safe - with low rates for target vessel thrombosis, myocardial infarction, late acquired aneurysms ~ effective — with TLR rate of 6.3% and an angiographic res
Slide 38: TAXUS V ISR - In Perspective
TAXUS V ISR - In Perspective Study Design -YPHER vs VBT TAXUS vs VBT 384 patients 396 patients il 6 months angio flu 9 month angio ffu 9 months clinical flu 9 months clinical flu RVD 22.5 and <3.5mm RVD 22.5 and <3.75mm Lesion =15 and <40mm Lesion $46mm no additional PCI additional PCI allowed in no
Slide 39: TAXUS V ISR - In Perspective
@4- TAXUS V ISR - In Perspective Baseline characteristics 9.3% insulin-treated 19.5% insulin treated 18.5 mm mean lesion length not reported 2.68 mm mean RVD not reported 81.9% B2IC lesions
Slide 40: TAXUS V ISR - In Perspective
@4- TAXUS V ISR - In Perspective Clinical 9-Month Outcomes 8.5% TLR 6.3% 10.8% TVR 10.5% 12.4% TVF 11.5% 1 (0.8%) Stent thrombosis (1.6%) ‘one patient would not be included under the CYPHER definition
Slide 41: TAXUS V ISR - In Perspective
TAXUS V ISR - In Perspective Angiographic Outcomes 0.27+0.65 mm Late Loss 0.29+0.54 mm at 6-Month analysis segment at 9-Month not reported Late Loss in-stent % Binary restenosis at 6-Month analysis segment not reported Binary restenosis in-stent a
Slide 42: TAXUS Express: Closing the Development Cycle from Simple to Complex
@u- TAXUS Express: Closing the Development Cycle from Simple to Complex Aeot, Mach 13,2005 ‘ACC Cowal Reseach Update 2
Slide 43: What is Next: TAXUS ATLAS as the First Second Generation DES
@4- What is Next: TAXUS ATLAS as the First Second Generation DES Aeot, Mach 13,2005 ‘ACC Cowal Reseach Update 8
Slide 44: Scientific
Be Scientific Detivering what's next.”
Slide 45: TAXUS Liberté Stent System Performance
TAXUS® Liberté™ Stent System Bostone. — Performance The good news: * Impacting international markets « Increasing revenue by approximately 16% * Converting accounts previously unable to convert The better news ¢ Not fully launched in largest international markets ¢ Maintaining share and ASP in crowd
Slide 46: International DES Space is Crowding
International DES Space is Crowding cBostong. Pan @ BIOTRONIK ( _—_— AUTAXUS' EXPRESS? Bei + Pipeline + Expectations
Slide 47: International TAXUS Liberté Stent Sales Increasing
International Boston, Scientific TAXUS® Li =-Stent Sales Increasing Conversion (%) + 100% + Launched in all EU countries & 14 Operations in IC + >65% Conversion; | 40% Target >70% at end of Q1'06 « ASP: Avg. 5% price premium over TAXUS 0% Express Q1'05 Q2'05 Q3'05 Q4'05 Q1'06E [3 TAXUS® Express?™ TA
Slide 48: DES Penetration and TAXUS Market Share
205 305 a4 '05 _» DES Penetration “= TAXUS Market Share (unit) ‘DES Penetration “Market Share 100% 60% on = “ 70%, | 1% 921% 50% 04, 60% 50% 40% L 30% | 20% + 10% 4 0% + entific *TAXUS steady *Cypher® down significantly *Endeavor™ hitting plateau *Endeavor™ share coming from Cypher® BSC Internal Est
Slide 49: TAXUS Liberté Launched in 65% of Int'l Market
TAXUS® Liberté™ Launched in 65% of gBostone Int'l Market, 35% itionalOpportunity TAXUS Liberté has launched in 14/ 21 IC markets; largest yet to come (Brazil, Australia, TAXUS Liberté launched in all ©2248) EU. In 4 months later, GDR, ESP, ITA, & UK gained 16% revenue oil Korea Taiwan fi Me Chil If
Slide 50: TAXUS Liberté Stent Design
TAXUS® Liberté” Stent Design Boston, Achieving the Opti. lance Conformability Deliverability Side Branch Access ‘This product is not yet approved for sale in the United States,
Slide 51: Balloon Withdrawal Reduced
Balloon Withdrawal Reduced Shea. Peak Force (grams) -_ Significant improvement in bench testing under identical conditions waa Express?™ | TAXUS®Liberté™ f) 300 20 3.5 x 16mm 20 | 200 a 200 3.0 x 146mm 150 § 180 Lea 100 8 100 ee mes _ | a ° | — . a 85% of evaluators rated TAXUS Liberté Well or Very
Slide 52: Advanced Deliverability of Liberté
Advanced Deliverability of Liberté™ Boston, Stent Drivi ‘BMS"Share in_.U.S. Aug ‘05 Sept Oct Nov Dec Jan'06 Feb SC internal Estimates.
Slide 53: Jul ‘Aug Sep Oct Nov Dec Jan Feb
Jul ‘Aug Sep Oct Nov Dec Jan Feb Sequential Sales Competitor supply, publications and campaign BSC internal Estimates.
Slide 54: Major DES Activities in '06
Major DES Activities in ‘06 Soa Q2 TES Assurance * ATLAS 9 mo * TAXUS VI + TINY Trial Enrollment Q3 Q4 + Xience* launch OUS + TAXUS®Liberté™ Launch *TAXUS® Express2™ + TCT: Expanded Matrix - TAXUS IV 4yr - 2.25/4.0 mm TAXUS V 2yr * TAXUS® Liberte™ - Launch Prep “Subject to closing of Guidant transac
Slide 55: DES Regulatory Update
DES Regulatory Update east * TAXUS® Liberté™ U.S. — final PMA module submitted — Launch expected Q4 ’06 * Xience* CE Mark Q1 ’06 — Launch expected Q3 ‘06 * TAXUS® Express “Japan — approval expected Q1 07 *Subject to closing of Guidant transaction BSC Internal Estimates
Slide 56: New Bands
New Bands New Tip/ Balloon Thin polymer sleeve ‘a = Bi-Segment™ Inner Shaft ‘New Stope™ Outer Shaft mT
Slide 57: TAXUS Apex Stent System
TAXUS® Apex™ Stent System eee Design Freeze Complete CE Submission 2H 2006 PMA Submission 2H 2007 Japan Submission 2H 2007 EU/IC Launch 1H 2007 U.S. Launch 1H 2008 SC internal Estimates.
Slide 58: Geometry designed for drug delivery
Geometry designed for drug delivery PERSS: New stent material- thin struts without compromise Increased flexibility & Conformability
Slide 59: TAXUS Barracuda System
TAXUS® Barracuda =e System gBostone Commercialization Design Freeze 1Q 2006 IDE Submission 2H 2006 CE Submission 2H 2007 PMA Submission 1H 2008 Japan Submission 2H 2008 EU/IC Launch 1H 2008 U.S. Launch 1H 2009 SC internal Estimates.
Slide 60: TAXUS Petal Bifurcation
TAXUS® Petal™ Bifurcation Bostone. Carina Coverage, Aligning Architecture =< |S Stent and BSC Drug- —™ oA _ Elution Technology Bifurcations are involved in 25-30% of all interventions
Slide 61: TAXUS Petal Bifurcation Status
TAXUS® Petal” Bifurcation Status Senne World-Class Technology — New stent design and material Lb — Apex’ based delivery system “ " ia OTAXUS Petal Stent o | Chronic drug-coated pre-clinical studies underway Promising acute performance Targeting end of 2006 to begin first human clinicals [BSC interna
Slide 62: DES Pipeline: Sustainable Advantage
DES Pipeline: Sustainable Advantage Beton. ao Only TAXUS provides incremental improvements year after year 2007 2008 2009 2 Xience™ * ZoMaxx™?
Slide 63: ealeaslalalelaslalale|a|lala|e@
——a 4 2005 2006 2007 2008 Qu ealeaslalalelaslalale|a|lala|e@ aa Guidewire FWEZCAS Indication & FWEZL: bicon NG Device FWEZ Small (2.25-3.5mm) —‘©-9mm) —_2.3F/Sheathless
Slide 64: Peripheral & Vascular Surgery Pipeline
ston, Peripheral & Vascular Surgery Pipeline SUentfic 2006 2007 2008 gi | g2 | 93 | o4 | a1 | 2 | os | oe [ar | @ Sentinol SE Stent SS PV Ultra 2 Cutting Balloon ZipWire Hydrophilic GW New Fusion Graft [BSC internal Estimates:
Slide 65: CABERNET
CABERNET FilterWire EZ ZA Conditions of Approval Letter
Slide 66: CV Core Business Summary
CV Core Business Summary gBostone Q1’06, US MS.Rankings Rank Cordis GDT MOT INTERVENTIONAL CARDIOLOGY Bare Metal Stents Balloon Catheters Guide Wires Guide Catheters Diagnostic Catheters Atherectomy IvUS Embolic Protection Fluid Management Vascular Sealing ss 0nR Ro2N5 eohoo PERIPHERAL / VASCULAR SU
Slide 67: Key Take-Aways
Key Take-Aways Senne ‘S Global Leadership (x-Japan) strengthening — U.S. TAXUS® share stable at 54% * Q4 TAXUS® Liberté™ Launch — Int'l TAXUS share stable 2 50% * TAXUS® Liberté™ Launch Expansion + Endeavor™ / Cypher® share exchange + Compelling pipeline, progressing steadily — Apex, Barracuda, Peta
Slide 68: Key Take-Aways
Key Take-Aways Bostone, _ Scientific + Warning Letter remediation making measured progress with new systems ¢ Guidant on track — VI Divestiture and close — Week of April 3% — Diversification and Growth * Cardiovascular / Full BSC continues strong performance
Slide 69: Scientific
Be Scientific Detivering what's next.”
Slide 70: Searchable text section of graphics shown above
Searchable text section of graphics shown above [L OGO] Analyst Meeting at ACC Introduction Larry Best March 13, 2006 [L OGO] Safe Harbor: Forward-Looking Statements This presentation contains “forward-looking statements,” including, among other statements, statements regarding the proposed business